羟氯喹作为附加治疗原发性膜性肾病的先导试验
这项单中心开放标签前瞻性研究纳入72例肾病综合征且肾活检证实的原发性膜性肾病患者,比较糖皮质激素联合免疫抑制剂与羟氯喹联合标准治疗的效果。结果显示羟氯喹组6个月蛋白尿显著降低,12个月复发率也显著低于标准治疗组。提示羟氯喹可能作为原发性膜性肾病的有效附加治疗。
要点
- 羟氯喹联合标准治疗6个月蛋白尿较标准治疗显著降低。
- 羟氯喹组12个月复发率显著低于标准治疗组。
- 羟氯喹可能作为原发性膜性肾病的附加治疗选项。
核心结论
- 羟氯喹可能作为原发性膜性肾病的有效附加治疗。
研究设计与样本
- 单中心、开放标签、前瞻性研究,纳入72例肾病综合征且肾活检证实的原发性膜性肾病患者。
- 41例接受糖皮质激素和免疫抑制剂,31例接受羟氯喹联合标准治疗。
- 随访3、6、9、12个月,比较蛋白尿、血清白蛋白、eGFR和复发率变化。
主要发现
- 两组基线特征无统计学显著差异。
- 羟氯喹组6个月蛋白尿较标准治疗组显著降低(1.2 [0.4-2.2] vs. 2.2 [1.0-3.8] g/d,P = 0.029)。
- 羟氯喹组12个月随访复发率显著低于标准治疗组(3.7% vs. 23.3%,P = 0.033)。
临床怎么用
- 对于原发性膜性肾病患者,可考虑在标准治疗基础上加用羟氯喹以降低蛋白尿和复发风险。
局限性
- 单中心、开放标签设计可能引入偏倚。
- 样本量较小(72例),结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney Disease Improving Global Outcomes guidelines indicate that glucocorticoids and immunosuppressants comprise the first therapeutic regimens after 4 to 6 months of treatment for high-risk primary membranous nephropathy (PMN). However, some patients cannot achieve complete or partial remission at 6 months. This study aimed to evaluate the efficacy of traditional immunotherapy combined with hydroxychloroquine (HCQ), a well-known immune regulator, in patients with PMN. METHODS: This was a single-center, open-label, prospective study. We recruited 72 patients with nephrotic syndrome and PMN proven by renal biopsy from May 2020 to June 2024. We compared changes in proteinuria, serum albumin levels, estimated glomerular filtration rate (eGFR), and relapse rate at 3, 6, 9, and 12 months follow-up in 41 patients who received glucocorticoid and immunosuppressant, and in 31 who received HCQ plus standard-of-care. RESULTS: Baseline characteristics showed no statistical significance between the 2 groups. However, the HCQ group showed significantly reduced proteinuria compared to standard-of-care group. A reduced proteinuria was seen at 6 months (1.2 [0.4-2.2] vs. 2.2 [1.0-3.8] g/d, P = 0.029) and the relapse rate with 12 months follow-up was also significantly decreased in the HCQ group compared to the standard-of-care group (3.7% vs. 23.3%, P = 0.033). CONCLUSIONS: HCQ may serve as an effective add-on therapy for PMN.
引用
- Yang H, Sun G, Yang X, et al. Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy. Kidney Int Rep. 2024. PMID: 39698370. doi:10.1016/j.ekir.2024.09.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。